Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers. - Inria - Institut national de recherche en sciences et technologies du numérique Accéder directement au contenu
Article Dans Une Revue Journal of Theoretical Biology Année : 2013

Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers.

Résumé

Although optimal control theory has been used for the theoretical study of anti-cancerous drugs scheduling optimization, with the aim of reducing the primary tumor volume, the effect on metastases is often ignored. Here, we use a previously published model for metastatic development to define an optimal control problem at the scale of the entire organism of the patient. In silico study of the impact of different scheduling strategies for anti-angiogenic and cytotoxic agents (either in monotherapy or in combination) is performed to compare a low-dose, continuous, metronomic administration scheme with a more classical maximum tolerated dose schedule. Simulation results reveal differences between primary tumor reduction and control of metastases but overall suggest use of the metronomic protocol.
Fichier principal
Vignette du fichier
BenzekryHahnfeldt_optimizationMetastasesV3.pdf (3.18 Mo) Télécharger le fichier
MathAppendix.pdf (216.16 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Format : Autre

Dates et versions

hal-00836032 , version 1 (20-06-2013)

Identifiants

Citer

Sebastien Benzekry, Philip Hahnfeldt. Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers.. Journal of Theoretical Biology, 2013, 335, pp.235-44. ⟨10.1016/j.jtbi.2013.06.036⟩. ⟨hal-00836032⟩

Collections

TDS-MACS
206 Consultations
6809 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More